Skip to content

Research

Our Technology

Exocure proprietary biotechnology harnesses the intrinisic power of exosomes to deliver advanced therapeutic solutions for important unmet clinical needs, such as cancer or severe inflammation.

Technology achievements to date:

  • Invention of new biotechnology to treat cancer or severe inflammation, including inflammatory eye disease, cytokine storm, and to provide highly efficient next generation exosome cosmeceuticals.
  • Invention of efficient and proprietary loading of exosomes with complicated cargos (peptides, siRNA, proteins).
  • Surface engineering achieving specific cell targeting.
  • Identification of synergistic anti-inflammatory functions.
  • Completion of R&D of synthetic bacterial vesicles for cancer, resulting in high impact publication and patent filing.
  • Loading of “synthetic bacterial vesicles” with immuno-oncology molecules, further increasing potency.
  • Development of highly efficient proprietary exosome isolation methods for manufacturing.

Exocure proprietary biotechnology

Exosomes are nanosized particles naturally released by human cells, and can reprogramme other cells by delivering advanced cargo molecules to the inside of recipient cells, without disturbing normal cell function.

Exocure proprietary biotechnology harnesses the intrinisic power of exosomes to deliver advanced therapeutic solutions for important unmet clinical needs, such as cancer or severe inflammation.

Exocure disease foci:

Seven own patents and three licensed patents on exosome-based technologies applicable for:

Metabolic diseases (marketable product in 2-3 years)

  • Type II Diabetes
  • Obesity

Cancer and infection (clinical trial in 1 year)

  • Cancer metastasis (melanoma or colon cancer)
  • Advanced preventive vaccines

Anti-inflammatory therapeutics (clinic in 2-3 years)

  • Dry Eye Disease (DED)
  • Cytokine storm
  • Lung injury

Cargo proteins and RNA

Exosomes allow for intracellular and cell-specific delivery, which provides a therapeutic platform to meet many unmet clinical needs.

Exocure has proprietary biotechnology loading exosomes with different types of molecules, which results in synergistic therapeutic function, significantly increasing efficacy, whilst reducing side-effects.